HomeCompanyTechnologyPipelineInvestors & MediaContact

We have developed the capability to engineer Hepatitis B virus (HBV)-specific T cells that can recognize HBV-expressing tumor cells and achieve targeted killing.HBV is the major etiologic agent for hepatocellular carcinoma (HCC) development, accounting for at least 50% cases of HCC worldwide and at least 80% of cases in Asia. HBV predisposes to the development of HCC by causing chronic inflammation and genome destabilization after DNA integration into the genome of hepatocytes. 

More than 80% of HBV-related HCC tumors have detectable HBV-DNA integration. Epitopes encoded by these integrated HBV-DNA can be assembled with major histocompatibility complex (MHC) class I molecules on cell surfaces and serve as ideal targets for T cells.  

Clinical Application

LioCyx-M is produced following current good manufacturing practice (cGMP) compliant principles in less than 2 weeks for clinical use. The general steps are as follows:

1. The patient undergoes leukapheresis to isolate white blood cells.

2. T cells from the patient are expanded and activated in Lion TCR’s GMP cell production facility.

3. Genetic material encoding our virus- or cancer-targeting TCR are introduced into the activated T cells by or electroporation.

4. The patient’s T cells now express the relevant TCR that target virus-infected or virus-related cancer cells.

5. Following phenotypic and functional validation, the TCR engineered T cells are infused back to the patient.


P065 Phase 1 study of autologous hepatitis B virus (HBV) specific T cell receptor (TCR) T cells, LioCyx M in unresectable HBV related hepatocellular carcinoma (HCC)

Wang et al. EASL Digital Liver Cancer Summit (2021)

O07 Immunological alterations induced by HBV-TCR T cell immunotherapy associates with treatment response of primary HBV related-HCC

Tan et al. EASL Digital Liver Cancer Summit (2021)

Immunosuppressive Drug Resistant Armored TCR T cells for immune-therapy of HCC in liver transplant patients

Hafezi et al. Hepatology (2020)

Phase I Study of LioCyx-M, Autologous Hepatitis B Virus (HBV)-Specific T cell receptor (TCR) T-cells, in Recurrent HBV-Related Hepatocellular Carcinoma (HCC) Post-Liver Transplantation

Chen W et al. Journal for ImmunoTherapy of Cancer (2020)

Use of LioCyx-M, autologous hepatitis B virus (HBV)-Specific T cell receptor (TCR) T-cells, in advanced HBV-related hepatocellular carcinoma (HCC)

Wang FS et al. Journal for ImmunoTherapy of Cancer (2020)

Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for Immunotherapy

Tan AT et al. Gastroenterology (2019)

TCRs in Development

Our library of TCRs recognizes viral peptides expressed on MHC Class I restricted for the Asian population.

We are actively extending our proprietary TCR therapy platform to target more viruses, particularly those prevalent in Asia, for example, HBV, EBV and CMV.